Unigene Laboratories, Inc. Notes Progress of Tarsa Therapeutics Phase III ORACAL Trial of its Oral Calcitonin for the Treatment of Postmenopausal Osteoporosis
BOONTON, N.J.--(BUSINESS WIRE)--Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) today noted that Tarsa Therapeutics has completed patient enrollment in the Phase III ORACAL trial of Tarsa’s oral calcitonin product for the treatment of postmenopausal osteoporosis. Unigene licensed the product to Tarsa and owns 26% of the company.